Scrip Asks What Does 2022 Hold for Biopharma
In Partnership with EDQM
In Partnership with EDQM
More from Strategy
Otsuka bested Vera on Phase III immunoglobulin A nephropathy data for proteinuria, but analysts wonder if the difference is especially meaningful.
The low-dose atropine eye drop slowed the progression of pediatric myopia by 30%.
EFPIA says reforms make the continent less attractive for innovative firms.
US green light will further expand sales of the prostate cancer blockbuster.
More from Business
Insights from Novotech on Evolving Trends Impacting Global Clinical Development
Delve into the challenges facing the NHS, from rising medicine costs to supply shortages, and how generics and branded generics can provide solutions for a more sustainable healthcare system
Access key stats from biotechs on the latest trends impacting oncology R&D, including therapeutic pipelines and clinical trial challenges, AI/ML, and a future outlook on innovation.
Gain exclusive insights into the biggest challenges biotechs face in oncology and uncover the latest opportunities to accelerate drug development.